Top Markets
#1 Black Phoenix Black Phoenix +828.57%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.40%
#3 Beam Beam +23.21%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +22.56%
#5 SAFEcoin SAFEcoin +20.80%
#6 Magma Finance Magma Finance +20.11%
#7 pipedog pipedog +18.82%
#8 Bless Bless +16.88%
#9 PondCoin PondCoin +16.70%
#10 THORChain THORChain +16.34%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Metis Techbio-p Metis Techbio-p

Metis Techbio-p

7666
Rank in Stocks #6111
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China,... Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
Share Price
$1.88
Market Cap
$2.22B
Change (1 day)
-0.81%
Change (1 year)
-
Country
CN
Trade Metis Techbio-p (7666)

Category

Healthcare
P/E ratio for Metis Techbio-p (7666)
P/E ratio as of 2026 TTM: 0
According to Metis Techbio-p latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Metis Techbio-p from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.